2026 Q1 -tulosraportti
Vain PDF
57 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 23.9. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 24.6. | ||
2025 Q4 -tulosraportti 25.3. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 17.9.2025 | ||
2025 Q1 -tulosraportti 27.6.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·12 t sittenFor the researchers, it's hard work, but for us shareholders, it's just a really solid announcement that's good enough, as we saw with Moderna yesterday. Good news is win-win for both shareholders and patients. Hope it goes well here too 😊
·13 t sittenDoes anyone know if Softox has tested its products on the Ebola virus?
Says AI Yes, the Norwegian company SoftOx Solutions has tested their technology against the Ebola virus in laboratory environments. They have confirmed that their disinfectant formula based on hypochlorous acid (HOCl) effectively kills viruses from the Filoviridae family, which includes Ebola.🔎 Laboratory Test vs. Medical TreatmentIt is important to distinguish between what the technology has been tested and approved for:Surface and hand disinfection: German independent institutes (Dr. Brill + Dr. Steinmann) have conducted tests documenting that the product has full virucidal effect, meaning it inactivates the Ebola virus on surfaces and skin.No internal medicine: Ebola is not an airborne infection, but is primarily transmitted through bodily fluids, wounds, and mucous membranes. The company's ongoing medical research into inhalation technology is aimed at respiratory infections and not specifically as an internal cure for Ebola.📊 Investment and Market Context (SOFTX)If you are examining SoftOx from a financial or investment perspective, you should be aware of the following framework conditions for biotech companies in this category:Defense programs: The technology is part of the EU's defense program COUNTERACT, which researches medical countermeasures against biological and chemical threats (including potential pandemic viruses and anthrax).⚠️ High risk: Biotech companies in development stages are associated with extremely high volatility. There is a risk of total loss of capital if clinical trials fail or commercialization does not materialize. Individual stocks like SoftOx Solutions (SOFTX) should always only constitute a smaller, speculative part of an otherwise broadly diversified portfolio.Do you want to know more about the specific laboratory results, or are you researching the stock in connection with the EU's COUNTERACT defense program?This is for information only.
·1 päivä sitten · MuokattuSoftOx's defense program has sky-high potential. SoftOx in the EU's defense program: "One of three key technologies" — what it actually means BACKGROUND: COUNTERACT AND EDF After the pandemic and the deteriorating security situation in Europe, the EU established the European Defence Fund (EDF) to ensure the continent's autonomy in critical defense technology. COUNTERACT is one of the largest medical projects within this framework: a consortium with 26 partners from 11 countries, with almost 49 million euro in EU support (total framework approx. 56 mill. euro) and a 60-month duration from December 2022. The coordinator is the French research commission CEA — one of Europe's most influential institutions — with partners such as the Robert Koch Institute (Germany), TNO (Netherlands), University of Copenhagen, NUI Galway, and the Norwegian FFI. Five universities, ten public research institutes, and eight private companies. THE CORE SoftOx's subsidiary SoftOx Defense Solutions received approx. 97 MNOK — approximately 19 % of the entire EU contribution, to a single partner. The company's Q2 2022 report states verbatim that "the SoftOx technology is one of three key technologies on which the grant is based", with six research institutions (FFI + five international) working directly with the technology. What is the significance? 1) Independent confirmation, not just IR. At the "Resilience Day" workshop in Arcachon on May 20, 2026 — co-organized by the EDF programs COUNTERACT and RESILIENCE — the bio-threat panel presented exactly three technology pillars: next-generation vaccines (CEA), SoftOx's "SIS 2.0", and monoclonal antibodies (Univ. of Amsterdam). SoftOx's Clinical Project Lead Elin Jørgensen gave the presentation "SIS 2.0 — potential game changer against inhaled biological threats". The fact that the EU's own program structure gives SoftOx one of three stages for bio-threats corroborates the "key technology" framing. 2) EDF pays for military development through Phase 1. The SIS-02 study (healthy volunteers, Galway) is now ongoing with the first participant enrolled in June 2026 — financed by COUNTERACT, not by the shareholders. The goal is a broad-spectrum antimicrobial solution (SIS) until Phase 1 is completed. The financial and strategic implication of this partnership is monumental for the Company and its shareholders. The military development path for the Company is approximately cash flow neutral. European defense funds pay some of the world's foremost research institutions to validate and optimize a finished product to which the Company ultimately retains all global commercial rights. 3) Dual-use synergy: the same SIS platform and the same clinical safety foundation (SIS-03 is ongoing in parallel in Denmark) drive both civilian and military development.
Very exciting, they also have great faith in Softox, that also means a lot, have a nice day and good luck ❤️🌞- ·1 päivä sittenI just read about Moderna, which has had positive results with a vaccine for melanoma, and the stock shot up by 128%. The thought strikes me if we will experience the same here. Because Softox is also in a positive phase regarding the testing of their medicine. It's a very exciting time for the company. Fingers crossed. PS, has anyone else had the pleasure of being on the "journey" Moderna has had?
·1 päivä sittenPaint dries faster than this moves today.
1 päivä sittenI am fairly certain it will go down further but i have gotten back in now. The fomo bacame to much to handle 🤣 got in at same level as you did peri 😅 had i stayed at 84 i would have gotten that thou 😅 ohhh well 22% more stocks than before for no extra investment 🤷
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
Vain PDF
57 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·12 t sittenFor the researchers, it's hard work, but for us shareholders, it's just a really solid announcement that's good enough, as we saw with Moderna yesterday. Good news is win-win for both shareholders and patients. Hope it goes well here too 😊
- ·13 t sittenDoes anyone know if Softox has tested its products on the Ebola virus?Says AI Yes, the Norwegian company SoftOx Solutions has tested their technology against the Ebola virus in laboratory environments. They have confirmed that their disinfectant formula based on hypochlorous acid (HOCl) effectively kills viruses from the Filoviridae family, which includes Ebola.🔎 Laboratory Test vs. Medical TreatmentIt is important to distinguish between what the technology has been tested and approved for:Surface and hand disinfection: German independent institutes (Dr. Brill + Dr. Steinmann) have conducted tests documenting that the product has full virucidal effect, meaning it inactivates the Ebola virus on surfaces and skin.No internal medicine: Ebola is not an airborne infection, but is primarily transmitted through bodily fluids, wounds, and mucous membranes. The company's ongoing medical research into inhalation technology is aimed at respiratory infections and not specifically as an internal cure for Ebola.📊 Investment and Market Context (SOFTX)If you are examining SoftOx from a financial or investment perspective, you should be aware of the following framework conditions for biotech companies in this category:Defense programs: The technology is part of the EU's defense program COUNTERACT, which researches medical countermeasures against biological and chemical threats (including potential pandemic viruses and anthrax).⚠️ High risk: Biotech companies in development stages are associated with extremely high volatility. There is a risk of total loss of capital if clinical trials fail or commercialization does not materialize. Individual stocks like SoftOx Solutions (SOFTX) should always only constitute a smaller, speculative part of an otherwise broadly diversified portfolio.Do you want to know more about the specific laboratory results, or are you researching the stock in connection with the EU's COUNTERACT defense program?This is for information only.
- ·1 päivä sitten · MuokattuSoftOx's defense program has sky-high potential. SoftOx in the EU's defense program: "One of three key technologies" — what it actually means BACKGROUND: COUNTERACT AND EDF After the pandemic and the deteriorating security situation in Europe, the EU established the European Defence Fund (EDF) to ensure the continent's autonomy in critical defense technology. COUNTERACT is one of the largest medical projects within this framework: a consortium with 26 partners from 11 countries, with almost 49 million euro in EU support (total framework approx. 56 mill. euro) and a 60-month duration from December 2022. The coordinator is the French research commission CEA — one of Europe's most influential institutions — with partners such as the Robert Koch Institute (Germany), TNO (Netherlands), University of Copenhagen, NUI Galway, and the Norwegian FFI. Five universities, ten public research institutes, and eight private companies. THE CORE SoftOx's subsidiary SoftOx Defense Solutions received approx. 97 MNOK — approximately 19 % of the entire EU contribution, to a single partner. The company's Q2 2022 report states verbatim that "the SoftOx technology is one of three key technologies on which the grant is based", with six research institutions (FFI + five international) working directly with the technology. What is the significance? 1) Independent confirmation, not just IR. At the "Resilience Day" workshop in Arcachon on May 20, 2026 — co-organized by the EDF programs COUNTERACT and RESILIENCE — the bio-threat panel presented exactly three technology pillars: next-generation vaccines (CEA), SoftOx's "SIS 2.0", and monoclonal antibodies (Univ. of Amsterdam). SoftOx's Clinical Project Lead Elin Jørgensen gave the presentation "SIS 2.0 — potential game changer against inhaled biological threats". The fact that the EU's own program structure gives SoftOx one of three stages for bio-threats corroborates the "key technology" framing. 2) EDF pays for military development through Phase 1. The SIS-02 study (healthy volunteers, Galway) is now ongoing with the first participant enrolled in June 2026 — financed by COUNTERACT, not by the shareholders. The goal is a broad-spectrum antimicrobial solution (SIS) until Phase 1 is completed. The financial and strategic implication of this partnership is monumental for the Company and its shareholders. The military development path for the Company is approximately cash flow neutral. European defense funds pay some of the world's foremost research institutions to validate and optimize a finished product to which the Company ultimately retains all global commercial rights. 3) Dual-use synergy: the same SIS platform and the same clinical safety foundation (SIS-03 is ongoing in parallel in Denmark) drive both civilian and military development.Very exciting, they also have great faith in Softox, that also means a lot, have a nice day and good luck ❤️🌞
- ·1 päivä sittenI just read about Moderna, which has had positive results with a vaccine for melanoma, and the stock shot up by 128%. The thought strikes me if we will experience the same here. Because Softox is also in a positive phase regarding the testing of their medicine. It's a very exciting time for the company. Fingers crossed. PS, has anyone else had the pleasure of being on the "journey" Moderna has had?
- ·1 päivä sittenPaint dries faster than this moves today.1 päivä sittenI am fairly certain it will go down further but i have gotten back in now. The fomo bacame to much to handle 🤣 got in at same level as you did peri 😅 had i stayed at 84 i would have gotten that thou 😅 ohhh well 22% more stocks than before for no extra investment 🤷
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 23.9. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 24.6. | ||
2025 Q4 -tulosraportti 25.3. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 17.9.2025 | ||
2025 Q1 -tulosraportti 27.6.2025 |
2026 Q1 -tulosraportti
Vain PDF
57 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 23.9. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 24.6. | ||
2025 Q4 -tulosraportti 25.3. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 17.9.2025 | ||
2025 Q1 -tulosraportti 27.6.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·12 t sittenFor the researchers, it's hard work, but for us shareholders, it's just a really solid announcement that's good enough, as we saw with Moderna yesterday. Good news is win-win for both shareholders and patients. Hope it goes well here too 😊
- ·13 t sittenDoes anyone know if Softox has tested its products on the Ebola virus?Says AI Yes, the Norwegian company SoftOx Solutions has tested their technology against the Ebola virus in laboratory environments. They have confirmed that their disinfectant formula based on hypochlorous acid (HOCl) effectively kills viruses from the Filoviridae family, which includes Ebola.🔎 Laboratory Test vs. Medical TreatmentIt is important to distinguish between what the technology has been tested and approved for:Surface and hand disinfection: German independent institutes (Dr. Brill + Dr. Steinmann) have conducted tests documenting that the product has full virucidal effect, meaning it inactivates the Ebola virus on surfaces and skin.No internal medicine: Ebola is not an airborne infection, but is primarily transmitted through bodily fluids, wounds, and mucous membranes. The company's ongoing medical research into inhalation technology is aimed at respiratory infections and not specifically as an internal cure for Ebola.📊 Investment and Market Context (SOFTX)If you are examining SoftOx from a financial or investment perspective, you should be aware of the following framework conditions for biotech companies in this category:Defense programs: The technology is part of the EU's defense program COUNTERACT, which researches medical countermeasures against biological and chemical threats (including potential pandemic viruses and anthrax).⚠️ High risk: Biotech companies in development stages are associated with extremely high volatility. There is a risk of total loss of capital if clinical trials fail or commercialization does not materialize. Individual stocks like SoftOx Solutions (SOFTX) should always only constitute a smaller, speculative part of an otherwise broadly diversified portfolio.Do you want to know more about the specific laboratory results, or are you researching the stock in connection with the EU's COUNTERACT defense program?This is for information only.
- ·1 päivä sitten · MuokattuSoftOx's defense program has sky-high potential. SoftOx in the EU's defense program: "One of three key technologies" — what it actually means BACKGROUND: COUNTERACT AND EDF After the pandemic and the deteriorating security situation in Europe, the EU established the European Defence Fund (EDF) to ensure the continent's autonomy in critical defense technology. COUNTERACT is one of the largest medical projects within this framework: a consortium with 26 partners from 11 countries, with almost 49 million euro in EU support (total framework approx. 56 mill. euro) and a 60-month duration from December 2022. The coordinator is the French research commission CEA — one of Europe's most influential institutions — with partners such as the Robert Koch Institute (Germany), TNO (Netherlands), University of Copenhagen, NUI Galway, and the Norwegian FFI. Five universities, ten public research institutes, and eight private companies. THE CORE SoftOx's subsidiary SoftOx Defense Solutions received approx. 97 MNOK — approximately 19 % of the entire EU contribution, to a single partner. The company's Q2 2022 report states verbatim that "the SoftOx technology is one of three key technologies on which the grant is based", with six research institutions (FFI + five international) working directly with the technology. What is the significance? 1) Independent confirmation, not just IR. At the "Resilience Day" workshop in Arcachon on May 20, 2026 — co-organized by the EDF programs COUNTERACT and RESILIENCE — the bio-threat panel presented exactly three technology pillars: next-generation vaccines (CEA), SoftOx's "SIS 2.0", and monoclonal antibodies (Univ. of Amsterdam). SoftOx's Clinical Project Lead Elin Jørgensen gave the presentation "SIS 2.0 — potential game changer against inhaled biological threats". The fact that the EU's own program structure gives SoftOx one of three stages for bio-threats corroborates the "key technology" framing. 2) EDF pays for military development through Phase 1. The SIS-02 study (healthy volunteers, Galway) is now ongoing with the first participant enrolled in June 2026 — financed by COUNTERACT, not by the shareholders. The goal is a broad-spectrum antimicrobial solution (SIS) until Phase 1 is completed. The financial and strategic implication of this partnership is monumental for the Company and its shareholders. The military development path for the Company is approximately cash flow neutral. European defense funds pay some of the world's foremost research institutions to validate and optimize a finished product to which the Company ultimately retains all global commercial rights. 3) Dual-use synergy: the same SIS platform and the same clinical safety foundation (SIS-03 is ongoing in parallel in Denmark) drive both civilian and military development.Very exciting, they also have great faith in Softox, that also means a lot, have a nice day and good luck ❤️🌞
- ·1 päivä sittenI just read about Moderna, which has had positive results with a vaccine for melanoma, and the stock shot up by 128%. The thought strikes me if we will experience the same here. Because Softox is also in a positive phase regarding the testing of their medicine. It's a very exciting time for the company. Fingers crossed. PS, has anyone else had the pleasure of being on the "journey" Moderna has had?
- ·1 päivä sittenPaint dries faster than this moves today.1 päivä sittenI am fairly certain it will go down further but i have gotten back in now. The fomo bacame to much to handle 🤣 got in at same level as you did peri 😅 had i stayed at 84 i would have gotten that thou 😅 ohhh well 22% more stocks than before for no extra investment 🤷
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt